



February 4th, 2022

MedVenture Partners, Inc.

Investment in Light Touch Technology Inc.

MPI-2 Investment Limited Partnership (MPI), managed and operated by MedVenture Partners, Inc., has completed its Series A (100 million JPY) investment in Light Touch Technology Inc.

Many of patients with Diabetes, over 400 million people worldwide, are required to measure blood glucose levels several times a day with their blood samples requiring finger pricks which may be painful and stressful procedures, involve infectious risk and require medical waste management.

Light Touch Technology Inc. successfully developed high intensity infrared laser technology, 1 billion times more intense compared to conventional light source (blackbody radiation), and established accurate non-invasive blood glucose technology. It enables blood glucose measurement without finger pricks and blood samples in less than five seconds.

MPI will not only financially support Light Touch Technology Inc.'s product development, but will also name Hajime Oshita, President of MPI, to the Board of Directors to accelerate the development and marketing of their product.

MPI will continue to actively invest in the medical device space while accelerating the growth of medical device startups in Japan, bridging overseas startups and Japanese companies, and contributing to the development of a medical device ecosystem in Japan.

Press Contact:

Kaz Watanabe

MedVenture Partners, Inc.

7F Nihonbashi Muromachi Mitsui Tower

Nihonbashi Muromachi 3-2-1 Chuo-ku, Tokyo 103-0022 JAPAN

Tel: +81-3-6273-4437